Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ferring Pharmaceuticals
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
- Specialty Pharmaceuticals
- Drug Discovery Tools
- Other Names / Subsidiaries
- BioSurface Engineering Technologies, Inc. (BioSET)
- Cytokine PharmaSciences, Inc. (Subsidiary: Controlled Therapeutics Ltd.)
- Ferring Pharmaceuticals
- Rebiotix, Inc.